Abliva AB (publ) (NEVPF) Stock Price, News & Analysis

Company Overview

Abliva AB (publ) is a clinical‐stage biopharmaceutical company dedicated to the discovery and development of small‐molecule therapeutics aimed at improving mitochondrial function. The company’s research focuses on rare neurometabolic and neurodegenerative diseases driven by mitochondrial dysfunction, with a pipeline built around proprietary metabolic modulators designed to restore cellular energy homeostasis. Abliva leverages expertise in mitochondrial biology and drug development to address unmet medical needs in conditions that currently lack approved therapies.

The company’s lead candidate, KL1333, is a novel metabolic modulator in clinical development for primary mitochondrial diseases characterized by impaired oxidative phosphorylation. KL1333 has advanced into Phase 2 studies, where its safety, tolerability and potential to enhance energy production in affected tissues are being evaluated. Alongside KL1333, Abliva maintains additional preclinical programs targeting other rare indications related to mitochondrial dysregulation, with the aim of expanding its therapeutic portfolio.

Founded in Sweden and headquartered in Lund, Abliva AB is listed on Nasdaq Stockholm and trades in the U.S. on the OTC market under the symbol NEVPF. The company conducts its research and development activities in Europe, while collaborating with academic institutions and clinical research organizations across North America. These partnerships enable Abliva to access specialized patient populations and accelerate the clinical advancement of its pipeline candidates.

Abliva’s management team brings together seasoned professionals from the biopharmaceutical industry, encompassing drug discovery, clinical development and regulatory affairs. The company’s governance structure includes an independent board of directors tasked with overseeing strategic initiatives, corporate governance and financial stewardship, all aimed at delivering novel therapeutic options for patients suffering from mitochondrial diseases.

Key Stats

• Today's Range: $0.03 to $0.03
• 50-Day Range: $0.03 to $0.03
• 52-Week Range: $0.01 to $0.04
• Volume: N/A
• Average Volume: 4,445 shs
• Market Capitalization: $11.28 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Company Calendar

• Today: 9/08/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: OTCMKTS:NEVPF
• CIK: N/A
• Web: www.neurovive.com
• Phone: (646) 275-6220
• Fax: 46-4-688-883-48
• Employees: 8
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$9.01 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -117.92%
• Return on Assets: -102.44%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 7.99
• Quick Ratio: 7.99

Sales & Book Value

• Annual Sales: $10 thousand
• Price / Sales: 1,128.43
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.02 per share
• Price / Book: 1.40

Miscellaneous

• Outstanding Shares: 403,010,000
• Free Float: N/A
• Market Cap: $11.28 million
• Optionable: Not Optionable
• Beta: -1.18